NeoGenomics (NEO) Reports In-Line Q1 EPS, Guides FY Revenue Below Estimates, FY EPS In-Line

NeoGenomics (NASDAQ: NEO) reported Q1 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $61.7 million versus the consensus estimate of $61.35 million.

GUIDANCE:

NeoGenomics sees FY2017 EPS of $0.17-$0.21, versus the consensus of $0.19. NeoGenomics sees FY2017 revenue of $255-265 million, versus the consensus of $264.6 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Is the S&P 500 in an "earnings bubble"? Goldman weighs in
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2